Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy
Titel:
Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy
Auteur:
Moore, M. Gill, S. Asmis, T. Berry, S. Burkes, R. Zbuk, K. Alcindor, T. Jeyakumar, A. Chan, T. Rao, S. Spratlin, J. Tang, P.A. Rothenstein, J. Chan, E. Bendell, J. Kudrik, F. Kauh, J. Tang, S. Gao, L. Kambhampati, S.R.P. Nasroulah, F. Yang, L. Ramdas, N. Binder, P. Strevel, E.